Stevanato Group略微遗漏了Q4收入,但提高了2026年的指导意见,指出对高价值药物包装的需求量很大。 Stevanato Group missed Q4 earnings slightly but raised 2026 guidance, citing strong demand for high-value drug packaging.

Stevanato Group于2026年3月4日报告2025年Q4收入,经调整的EPS为0.17欧元,略低于0.20欧元的共识,尽管收入逐年增长4.8%。 Stevanato Group reported Q4 2025 earnings on March 4, 2026, with adjusted EPS of €0.17, slightly below the €0.20 consensus, though revenue rose 4.8% year-over-year. 2025年全年收入增长7%(按不变货币计算为9%),原因是对高价值药品包装,特别是GLP-1治疗和生物学的强劲需求。 Full-year 2025 revenue grew 7% (9% at constant currency), driven by strong demand for high-value pharmaceutical packaging, particularly GLP-1 therapies and biologics. 该公司将其2026年EPS指导提高到0.690-0.730欧元,预计收入约为15亿欧元。 The company raised its 2026 EPS guidance to €0.690–0.730, projecting revenue of approximately €1.5 billion. Stevanato强调高价值解决方案、扩大利润幅度和持续的能力投资创纪录的收入, Despite a modest EPS miss, Stevanato highlighted record revenue from high-value solutions, expanded margins, and ongoing capacity investments. 股价在新闻中暴涨,反映出投资者对其长期增长前景的信心。 The stock surged on the news, reflecting investor confidence in its long-term growth outlook.